# Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype

> **NCT01066338** · — · UNKNOWN · sponsor: **Samsung Medical Center** · enrollment: 500 (estimated)

## Conditions studied

- Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01066338
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2010-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01066338

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01066338, "Genome-wide Pharmacogenetic Candidate Gene Single Nucleotide Polymorphism (SNP) Array-based Approach to Predict Chemoresponse and Survival in Patients With Acute Myeloid Leukemia With Normal Karyotype". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01066338. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*